ArticleBMC infectious diseases2021
People living with HIV easily lose their immune response to SARS-CoV-2: result from a cohort of COVID-19 cases in Wuhan, China.
Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort study.Journal of virology · 2025Trial
- SARS-CoV-2 IgG seropositivity among people living with and without HIV in the first year of the COVID-19 pandemic in Haiti and Tanzania.IJID regions · 2026Article
- Article
- Clinical outcomes and immunological response to SARS-CoV-2 infection among people living with HIV.Experimental biology and medicine (Maywood, N.J.) · 2024Review
- Article
- Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames?Current HIV/AIDS reports · 2023Review
- Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination.Frontiers in immunology · 2023Article
- Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infection-Final Update of a Living, Rapid Review.Annals of internal medicine · 2023Review
- Lower SARS-CoV-2-specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19.JCI insight · 2022Observational
- SARS-CoV-2 humoral and cellular immune responses in COVID-19 convalescent individuals with HIV.The Journal of infection · 2022Article
- Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals.AIDS research and therapy · 2022Article
- HIV and SARS-Cov-2 Co-Infection: A Local Perspective.Infectious diseases & clinical microbiology · 2022Article
- Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions.Translational research : the journal of laboratory and clinical medicine · 2022Review
- Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV.Frontiers in immunology · 2022Article
- Risk of SARS-CoV-2 Infection Among People Living With HIV in Wuhan, China.Frontiers in public health · 2022Article
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
backgroundTo date, whether the immune response for SARS-CoV-2 infection among people living with HIV(PLWH) is different from HIV-naïve individuals is still not clear.
methodsIn this cohort study, COVID-19 patients admitted to hospitals in Wuhan between January 15 and April 1, 2020, were enrolled. Patients were categorized into PLWH and HIV-naïve group. All patients were followed up regularly (every 15 days) until November 30, 2020, and the immune response towards SARS-CoV-2 was observed.
resultsTotally, 18 PLWH and 185 HIV-naïve individuals with COVID-19 were enrolled. The positive conversion rates of IgG were 56% in PLWH and 88% in HIV-naïve patients respectively, and the peak was on the 45th day after COVID-19 onset. However, the positive rate of IgG dropped to 12% in PLWH and 33% among HIV-naïve individuals by the end of the study. The positive conversion rate of IgG among asymptomatic carriers is significantly lower than that among patients with moderate disease (AOR = 0.24, 95% CI 0.07-0.85). PLWH had a lower IgG seroconversion rate (AOR = 0.11, 95% CI 0.03-0.39) and shorter IgG duration (AHR = 3.99, 95% CI 1.43-11.13) compared to HIV-naïve individuals. Patients with higher lymphocyte counts at onset had a lower positive conversion rate (AOR = 0.30, 95% CI 0.10-0.87) and shorter duration for IgG (AHR = 4.01, 95% CI 1.78-9.02).
conclusionsThe positive conversion rate of IgG for SARS-CoV-2 was relatively lower and quickly lost in PLWH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.